NCT00832871

Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

INST 0817: Compassionate Use of Mifepristone

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: New Mexico Cancer Research Alliance · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see if mifepristone prevents worsening of your cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. It has not been approved by the Food and Drug Administration for use in the treatment of cancer. It is unlicensed in the United States for your condition. However, previous work has indicated that mifepristone may be useful due to how it works. It is being made available for use in the United States for compassionate use through the Feminist Majority Foundation.

Detailed description

This is a compassionate use of mifepristone treatment for patients with conditions that could respond to an antiprogesterone agent, including: * Meningioma. * Breast cancer * Colon Cancer * Endometrial Stromal Sarcoma * Bilateral Chronic Central Serous Retinopathy * Cushing's Syndrome * Metastatic Adrenocortical Cancer * Ovarian Cancer * Other conditions as determined by the attending physicians

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	Mifepristone	Mifepristone 200 mg will be administered orally

Timeline

• Start date: 2008-11-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2009-01-30
• Last updated: 2018-06-29
• Results posted: 2016-08-02

Locations

1 site across 1 country: United States